Valuation: Telix Pharmaceuticals Limited

Market Cap 5.31B 3.8B 3.26B 3.05B 2.79B 5.24B 364B 36.03B 14.05B 183B 14.28B 13.97B 605B P/E 2026 *
238x
P/E 2027 * 162x
Enterprise Value 5.74B 4.11B 3.52B 3.3B 3.02B 5.66B 393B 38.94B 15.18B 198B 15.44B 15.1B 654B EV / Sales 2026 *
4.18x
EV / Sales 2027 * 3.68x
Free-Float
83.35%
Yield 2026 *
-
Yield 2027 * -
1 day-10.13%
1 week-6.63%
Current month+9.92%
1 month+5.11%
3 months+17.27%
6 months+49.76%
Current year+39.46%
1 week 15.62
Extreme 15.62
18.13
1 month 13.95
Extreme 13.95
18.13
Current year 8.26
Extreme 8.26
18.13
1 year 8.26
Extreme 8.26
19.07
3 years 8.2
Extreme 8.2
31.97
5 years 3.55
Extreme 3.55
31.97
10 years 0.46
Extreme 0.46
31.97
Manager TitleAgeSince
Chief Executive Officer 51 02/01/2017
Director of Finance/CFO 61 30/07/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 51 02/01/2017
Chairman 66 02/02/2026
Director/Board Member 68 18/06/2018
Date Insider Type Main position Quantity % Market Cap.
06/11/25 Fiscal year

Founder

100,708 0.0298%
17/06/25 Free

Founder

2,595 0.0008%
17/06/25 Free

Founder

166,483 0.0494%
Change 5-day change 1-year change 3-year change Capi.($)
-10.13%-6.63%-14.78%+58.26% 3.8B
+1.09%+5.26%+4.52%+26.24% 51.61B
-1.07%+2.82%+465.96%+586.75% 44.89B
+1.47%+9.79%+35.92%+21.40% 42.77B
+1.44%+7.77%+19.38%+92.75% 42.58B
-0.93%-4.33%+16.18%+53.76% 31.82B
+1.32%+7.30%+33.89%+150.10% 17.33B
-0.60%+1.93% - - 16.63B
+0.03%+3.41%+6.55%+32.10% 14.76B
+1.28%+5.41%+82.40%+47.43% 14.09B
Average -0.61%+3.33%+72.22%+118.75% 28.03B
Weighted average by Cap. +0.34%+4.56%+97.92%+145.03%

Financials

2026 *2027 *
Net sales 1.37B 983M 842M 788M 721M 1.35B 94.03B 9.31B 3.63B 47.24B 3.69B 3.61B 156B 1.58B 1.13B 968M 906M 830M 1.56B 108B 10.71B 4.18B 54.34B 4.25B 4.15B 180B
Net income 25.06M 17.96M 15.39M 14.4M 13.18M 24.73M 1.72B 170M 66.33M 863M 67.44M 65.97M 2.86B 19.9M 14.26M 12.22M 11.43M 10.46M 19.64M 1.36B 135M 52.67M 686M 53.56M 52.39M 2.27B
Net Debt 429M 308M 263M 246M 226M 423M 29.43B 2.91B 1.14B 14.78B 1.15B 1.13B 48.89B 498M 357M 306M 286M 262M 491M 34.13B 3.38B 1.32B 17.15B 1.34B 1.31B 56.71B
Logo Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Employees
1,152
Date Price Change Volume
21/08/26 A$15.62 -10.13% 4,587,381
20/08/26 A$17.38 +3.21% 5,205,523
19/08/26 A$16.84 +0.48% 974,002
18/08/26 A$16.76 +1.88% 2,024,589
17/08/26 A$16.45 -1.67% 1,279,956
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
15.62AUD
Average target price
23.44AUD
Spread / Average Target
+50.04%

Quarterly revenue - Rate of surprise